Effect of alternate-week versus continuous dexamethasone scheduling on the risk of osteonecrosis in paediatric patients with acute lymphoblastic leukaemia: Results from the CCG-1961 randomised cohort trial

The Lancet Oncology

Volumn 13, Issue 9, 2012, Pages 906-915

  Mattano, Leonard A ^a   Devidas, Meenakshi ^b   Nachman, James B ^c   Sather, Harland N ^d   Hunger, Stephen P ^e   Steinherz, Peter G ^f,g   Gaynon, Paul S ^h   Seibel, Nita L ⁱ  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d CHILDREN S ONCOLOGY GROUP   (United States)

^e Children's Hospital Colorado   (United States)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^h UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

ⁱ NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; METHOTREXATE; PREDNISONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BONE NECROSIS; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; FEMALE; HAZARD RATIO; HIGH RISK PATIENT; HUMAN; INCIDENCE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PEDIATRICS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SCHOOL CHILD; TREATMENT RESPONSE;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INCIDENCE; INFANT; MALE; METHOTREXATE; OSTEONECROSIS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PREDNISONE; SEX DISTRIBUTION; SEX FACTORS; SURVIVAL RATE; TREATMENT OUTCOME; VINCRISTINE; YOUNG ADULT;

EID: 84865541969     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(12)70274-7     Document Type: Article

References (30)

1. te Winkel ML, Pieters R, Hop WC, et al. Prospective study on incidence, risk factors, and long-term outcome of osteonecrosis in pediatric acute lymphoblastic leukemia. J Clin Oncol 2011, 29:4143-4150.
2. Gaynon PS, Trigg ME, Heerema NA, et al. Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995. Leukemia 2000, 14:2223-2233.
3. Moricke A, Zimmermann M, Reiter A, et al. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia 2010, 24:265-284.
4. Kaste SC, Karimova EJ, Neel MD Osteonecrosis in children after therapy for malignancy. AJR Am J Roentgenol 2011, 196:1011-1018.
5. Kawedia JD, Kaste SC, Pei D, et al. Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. Blood 2011, 117:2340-2347.
6. Marchese VG, Connolly BH, Able C, et al. Relationships among severity of osteonecrosis, pain, range of motion, and functional mobility in children, adolescents, and young adults with acute lymphoblastic leukemia. Phys Ther 2008, 88:341-350.
7. Elmantaser M, Stewart G, Young D, Duncan R, Gibson B, Ahmed SF Skeletal morbidity in children receiving chemotherapy for acute lymphoblastic leukaemia. Arch Dis Child 2010, 95:805-809.
8. Arico M, Boccalatte MF, Silvestri D, et al. Osteonecrosis: an emerging complication of intensive chemotherapy for childhood acute lymphoblastic leukemia. Haematologica 2003, 88:747-753.
9. Burger B, Beier R, Zimmermann M, Beck JD, Reiter A, Schrappe M Osteonecrosis: a treatment related toxicity in childhood acute lymphoblastic leukemia (ALL)-experiences from trial ALL-BFM 95. Pediatr Blood Cancer 2005, 44:220-225.
10. Mattano LA, Sather HN, Trigg ME, Nachman JB Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: a report from the Children's Cancer Group. J Clin Oncol 2000, 18:3262-3272.
11. Patel B, Richards SM, Rowe JM, Goldstone AH, Fielding AK High incidence of avascular necrosis in adolescents with acute lymphoblastic leukaemia: a UKALL XII analysis. Leukemia 2008, 22:308-312.
12. Fan C, Cool JC, Scherer MA, et al. Damaging effects of chronic low-dose methotrexate usage on primary bone formation in young rats and potential protective effects of folinic acid supplementary treatment. Bone 2009, 44:61-70.
13. Yang L, Boyd K, Kaste SC, Kamdem Kamdem L, Rahija RJ, Relling MV A mouse model for glucocorticoid-induced osteonecrosis: effect of a steroid holiday. J Orthop Res 2009, 27:169-175.
14. Yang L, Panetta JC, Cai X, et al. Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia. J Clin Oncol 2008, 26:1932-1939.
15. Bostrom BC, Sensel MR, Sather HN, et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 2003, 101:3809-3817.
16. Ito C, Evans WE, McNinch L, et al. Comparative cytotoxicity of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. J Clin Oncol 1996, 14:2370-2376.
17. Nachman JB, Sather HN, Sensel MG, et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med 1998, 338:1663-1671.
18. Seibel NL, Steinherz PG, Sather HN, et al. Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood 2008, 111:2548-2555.
19. Gray RJ A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988, 16:1141-1154.
20. Kaplan E, Meier P Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-481.
21. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977, 35:1-39.
22. Breslow NE Analysis of survival data under the proportional hazards model. Int Stat Rev 1975, 43:45-58.
23. Miyanishi K, Yamamoto T, Irisa T, et al. Bone marrow fat cell enlargement and a rise in intraosseous pressure in steroid-treated rabbits with osteonecrosis. Bone 2002, 30:185-190.
24. Motomura G, Yamamoto T, Miyanishi K, Yamashita A, Sueishi K, Iwamoto Y Bone marrow fat-cell enlargement in early steroid-induced osteonecrosis-a histomorphometric study of autopsy cases. Pathol Res Pract 2005, 200:807-811.
25. Laroche M Intraosseous circulation from physiology to disease. Joint Bone Spine 2002, 69:262-269.
26. Weinstein RS, Nicholas RW, Manolagas SC Apoptosis of osteocytes in glucocorticoid-induced osteonecrosis of the hip. J Clin Endocrinol Metab 2000, 85:2907-2912.
27. te Winkel ML, Appel IM, Pieters R, van den Heuvel-Eibrink MM Impaired dexamethasone-related increase of anticoagulants is associated with the development of osteonecrosis in childhood acute lymphoblastic leukemia. Haematologica 2008, 93:1570-1574.
28. Spencer JD, Brookes M Avascular necrosis and the blood supply of the femoral head. Clin Orthop Relat Res 1988, 235:127-140.
29. Relling MV, Yang W, Das S, et al. Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemia. J Clin Oncol 2004, 22:3930-3936.
30. McNeer JL, Nachman JB The optimal use of steroids in paediatric acute lymphoblastic leukaemia: no easy answers. Br J Haematol 2010, 149:638-652.